Internal Medicine, Endocrinology, Diabetes, & Metabolism · Miami, FL
NPI
1053378893
Since 2006
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
3661 S Miami Ave, # 505
Miami, FL, 33133
Phone (305) 859-9837
Groups this clinician bills Medicare through
Medicare paid, 2024
$105K
1,651 services
Medicare patients, 2024
376
Average age 77
Drug cost, 2024
$5.4M
11,035 prescriptions
Company payments, 2025
$1,814
From 25 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Hernan R Baquerizo was code 99214 (office e&m - established), 438 times for 267 patients. In total Hernan R Baquerizo billed 1,651 services in 20 codes, and Medicare paid $105K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-03-07.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 438 | 267 | $99.93 | $44K |
| 82962 Clinical Chemistry | Office | 410 | 181 | $3.21 | $1,316 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 177 | 114 | $14.49 | $2,566 |
| 99215 Office E&M - Established | Office | 112 | 112 | $141.79 | $16K |
| 95251 Test - Miscellaneous | Office | 87 | 44 | $30.27 | $2,634 |
| 99223 Hospital E&M - Initial | Facility | 69 | 59 | $155.18 | $11K |
| 99232 Hospital E&M - Subsequent | Facility | 66 | 25 | $70.98 | $4,685 |
| 76536 Ultrasound - Nonspecific | Office | 59 | 57 | $84.65 | $4,995 |
| 99233 Hospital E&M - Subsequent | Facility | 54 | 26 | $106.36 | $5,744 |
| 83036 Blood Count | Office | 49 | 41 | $9.52 | $466 |
| 99204 Office E&M - New | Office | 47 | 47 | $146.83 | $6,901 |
| 99213 Office E&M - Established | Office | 39 | 35 | $77.27 | $3,013 |
| 96372 Injection Administration | Office | 15 | 12 | $10.93 | $164 |
| 95249 Test - Miscellaneous | Office | 12 | 12 | $54.37 | $652 |
By year: 2022 $119K for 1,695 services; 2023 $107K for 1,512 services; 2024 $105K for 1,651 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 82962 Clinical Chemistry | 410 | 181 | $3.21 | $1,316 |
| 83036 Blood Count | 49 | 41 | $9.52 | $466 |
Medicare prescription drug claims, 2024
In 2024, the drug Hernan R Baquerizo prescribed most often to Medicare patients was Ozempic (Semaglutide), with 1,291 prescriptions and refills. In total Hernan R Baquerizo wrote 11,035 Medicare prescriptions that cost $5.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ozempic Semaglutide | 1,291 | 1,511 | 200 | $1.5M |
| Synthroid Levothyroxine Sodium | 1,003 | 2,481 | 273 | $114K |
| Pioglitazone Hcl Generic | 778 | 1,811 | 221 | $5,870 |
| Glimepiride Generic | 773 | 1,683 | 217 | $4,903 |
| Xigduo Xr Dapaglifloz Propaned/Metformin | 447 | 726 | 85 | $406K |
| Mounjaro Tirzepatide | 294 | 358 | 43 | $386K |
| Synjardy Xr Empagliflozin/Metformin Hcl | 287 | 408 | 62 | $246K |
| Metformin Hcl Generic | 282 | 632 | 90 | $1,517 |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 236 | 458 | 88 | $18K |
| Janumet Sitagliptin Phos/Metformin Hcl | 235 | 355 | 46 | $195K |
| Toujeo Max Solostar Insulin Glargine,hum.Rec.Anlog | 235 | 374 | 59 | $162K |
| Jardiance Empagliflozin | 191 | 304 | 47 | $177K |
| Farxiga Dapagliflozin Propanediol | 180 | 291 | 36 | $167K |
| Lyumjev Kwikpen U-100 Insulin Lispro-Aabc | 164 | 231 | 46 | $93K |
| Trulicity Dulaglutide | 160 | 208 | 39 | $205K |
Brand drugs: 6,562 claims; generic drugs: 3,955 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Hernan R Baquerizo $1,814 ($1,814 in general payments such as food, travel and fees) from 25 companies. The largest payer was Amgen Inc. with $193.
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. AMGN | 8 | $193 |
| Amneal Pharmaceuticals LLC AMRX | 9 | $175 |
| Corcept Therapeutics CORT | 6 | $156 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 4 | $128 |
| Xeris Pharmaceuticals, Inc. | 6 | $122 |
| Novo Nordisk Inc NVO | 4 | $101 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $100 |
| Lilly USA, LLC LLY | 5 | $89.71 |
| Abbvie Inc. ABBV | 5 | $89.15 |
| Abbott Laboratories ABT | 4 | $89.02 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.